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Abstract  
 
Background: The relation between changes in NT-proBNP and renal function has commonly 
been studied using multiple regressions, which may ignore the complexity of relations 
between related variables.          
Methods and Results: Data were collected from patients referred with suspected heart 
failure (HF) to a community service. Structural equation modelling (SEM) was used to assess 
the association between changes in NT-proBNP at 1 year, and other pre-specified variables 
including age, sex, BMI, eGFR, loop diuretics and ACE inhibitor. Of 1006 patients with a 
follow-up NT-proBNP at 1 year, 882 (88%) had HF. The baseline median age was 72 (IQR: 
63-78) years, 732 (73%) were men, 668 (66%) had left ventricular systolic dysfunction and 
769 (76%) had NT-proBNP>400pg/ml. For all patients at 1 year, 243 (24%) patients had at 
least a 50% reduction in NT-proBNP, and 199 (20%) had at least a 50% increase, only 40 
(3%) had <3% change. Change in NT-proBNP was strongly associated with baseline NT-
proBNP (the standardized coefficient (r) = 0.73, p<0.001). The change in NT-proBNP was 
not associated with changes in eGFR, and was indirectly related with age, BMI, eGFR and 
loop diuretics (p<0.01 for all).   
Conclusions: Baseline NT-proBNP was the main determinant of change in NT-proBNP at 
one year.   
 
 
  
Introduction 
N-terminal pro-B-type natriuretic peptide (NT-proBNP) and renal dysfunction measured by 
urea or creatinine are strongly related to prognosis in patients with chronic heart failure 
(CHF). The higher the NT-proBNP and the worse the renal function, the worse the outcome.  
There are strong positive associations between adverse outcome and age, NT-proBNP, urea 
or creatinine.1, 2, 3, 4 There is a moderate, but significant, relationship between NT-proBNP 
and renal function.5, 6, 7 The better the renal function, the lower the NT-proBNP. Renal 
dysfunction affects NT-proBNP; 8, 9, 10, 5 but a raised NT-proBNP concentration almost 
defines that heart failure is present, regardless of the severity of renal dysfunction.5 NT-
proBNP is stronger predictor of outcome than renal function.11, 12 Studies further indicate that 
changes in NT-proBNP are significantly associated with mortality.13, 14 Patients with a fall in 
NT-proBNP have a better prognosis, and those with a rise have a worse prognosis. 
The factors associated with change in NT-proBNP include age, sex and body mass index 
(BMI). There is a positive relationship between age and NT-proBNP.15 16 Women were more 
likely to have a high NT-proBNP,17 and there is an inverse relation between BMI and NT-
proBNP.18 19    
In general, the inter-relationships between NT-proBNP, urea or creatinine, age and BMI have 
principally been studied by traditional multiple linear regression analysis, which explores a 
correlation between one dependent variable and the number of independent variables; this 
may ignore the complexity of relations between related variables. The purpose of the study 
was to use structure equation modes (SEM) path analysis20 to assess the relations between 
changes in NT-proBNP at 1 year and pre-specified variables known to be associated with 
NT-proBNP: age, sex, BMI, eGFR, loop diuretics, ACE inhibitor (ACEi). Changes in BMI 
and changes in eGFR were also considered. Our hypothesis was that absolute changes in NT-
proBNP during the first year’s follow up are related to baseline value of NT-proBNP and 
renal function and also related to age, loop diuretics and changes in renal function (Figure 1). 
  
Methods 
Study population 
Patients referred for the assessment of possible heart failure to a local heart failure clinic 
(Kingston-upon-Hull, UK) between the years 2002 and 2010 had symptoms, signs, electro- 
and echocardiograms recorded and blood samples taken for routine haematology and 
biochemistry including urea. The NT-proBNP samples were collected in ethylene-diamine-
tetra-acetic tubes, spun at 3000 r.p.m for 15 minutes in a cooled (4°C) centrifuge and the 
plasma was stored at -80°C until batch analysed. The assay used was the Elecsys proBNP 
(Roche Diagnostics, Basel, Switzerland). eGFR was calculated using modification of diet in 
renal disease (MDRD) formula based on 4 variables: serum creatinine, age, ethnicity and 
gender. Patients had further routine clinic visits at one year.  
Heart failure was defined as: symptoms compatible with a diagnosis of heart failure in the 
presence of: either left ventricular ejection fraction (LVEF) <40% (or equivalent) or NT-
proBNP>400pg/ml. All patients provided written informed consent for their data to be used 
and the study was carried out in accordance with the Declarations of Helsinki and the 
European Standards for Good Clinical Practice. Ethical approval was granted by the Hull and 
East Yorkshire Local Research Ethics Committee.  
 
Statistical analysis 
The characteristics of patients are described by three different groups: a) all patients; b) heart 
failure; and c) patients in whom heart failure was excluded. Continuous variables are 
expressed as median and inter-quartile range and categorical variables as frequency and 
proportion. The continuous variables were tested for normality of distribution using 
Kolmogorov-Smirnov test. Structural equation modelling (SEM) was used to study 
associations between changes in NT-proBNP with pre-specified variables included baseline 
level NT-proBNP, eGFR, age, sex, BMI, loop diuretics, ACE inhibitor, changes in BMI and 
changes in eGFR. The change was measured as an absolute change between baseline and 1 
year follow-up visit. Log transformation of NT-proBNP was used to meet the assumption of 
the model. Scatter plots and Pearson correlation coefficients were used initially to investigate 
correlations. 
We used path analysis, a special case of structural equation modelling (SEM) 20 21 in which a 
number of multiple regression models is considered simultaneously.  SEM explores more 
complex relationships between variables than traditional regression analysis and includes 
measurement error. SEM path modelling links direct and indirect variables through a medium 
variable, and thus an individual variable can be both an independent variable and a dependent 
variable at the same time. There are two stages to path analysis: an initial path model is 
constructed; and then the relative strength of each independent variable on the dependent 
variable is estimated. We estimated the model parameters using maximum likelihood 
estimation; chi-square, Comparative Fit Index (CFI)22 and Root Mean Square Error of 
Approximation (RMSEA)23 were used to evaluate the goodness of model fit. Chi-
square>0.05, RMSEA<0.05 and CFI>0.9 indicate that the model fits the data well. 
Assumptions of linearity were tested in each linear regression. Statistical analysis was carried 
out using SPSS 19 software. The level of statistical significance was set at p=0.05 with two 
tails. 
 
Results 
Patient characteristics are shown in Table 1. Of 1006 patients with a follow-up NT-proBNP 
at 1 year, the median age was 72 (IQR: 63-78) years, 732 (73%) were men, 662 (66%) had 
LVSD and 769 (76%) had NT-proBNP>400pg/ml at baseline. Age, urea, creatinine, left atrial 
dimension and heart rate were higher, and eGFR, QRS width, systolic BP and BMI were 
lower, in patients with HF compared with those without HF. For all patients at one year, 243 
(24%) patients had at least a 50% reduction in NT-proBNP, 199 (20%) had at least a 50% 
increase. Only 40 (3%) had <3% change (Figure 2).  
Table 2 shows the changes in variables at one year for the whole population and for patients 
with HF. The median NT-proBNP fell but renal function worsened at one year follow up 
compared with baseline for both populations (p<0.001 for all). There was a strong linear 
correlation between baseline BMI and changes in BMI at 1year (r=0.86, p<0.001). The 
scatter plots in Figure 3-4 showed the relations between baseline and 1 year for NT-proBNP 
and eGFR, respectively. 
The SEM model fitted the data well (chi-square = 18.55, df = 10, p=0.05, CFI = 0.995, 
RMSEA = 0.029) implies that there is no reason to reject the relationships hypothesized in 
the original model. Table 3 shows the results. Change in NT-proBNP was most strongly 
related to baseline NT-proBNP (the standardized coefficient (r) was 0.73, p<0.001). Lower 
eGFR at baseline was slightly associated with an increase in NT-proBNP (p=0.06), and there 
was a weak negative correlation between change in eGFR and change in NT-proBNP 
(p=0.07). Change in NT-proBNP was not related to age and loop diuretics. The model 
accounted for 56% of the variance in change NT-proBNP at 1 year. Baseline NT-proBNP 
was strongly, positively related to age and taking loop diuretics (p<0.01 for all), and was 
negatively related to eGFR and BMI (p<0.01). Change in BMI were negatively related to 
baseline BMI and age (r=-0.30 for baseline BMI, r=-0.14 for age, p <0.01 for both), this 
means that the higher the BMI at baseline, the greater decrease in BMI at 1 year. Change in 
BMI was also slightly related with taking loop diuretics (r=0.07, p=0.01). Changes in eGFR 
were negatively correlated to age, baseline eGFR and baseline NT-proBNP (p<0.01 for all). 
In addition, there was a strong negative correlation between age and eGFR (r=-0.46; 
p<0.001), and a negative correlation between age and BMI (r=-0.23, p<0.01). 
There were the potential relationships between baseline age, eGFR, loop diuretics and BMI 
with changes in NT-proBNP due to the strong correlation between changes in NT-proBNP 
and baseline NT-proBNP. Creatinine and urea were not included as they are highly correlated 
with eGFR. The similar results were found in patients with HF (not shown). The final 
relations between changes in NT-proBNP at 1 year with the other variables were shown in 
Figure 5. 
 
Discussion  
The structural equation modelling method used in this study demonstrated that change in NT-
proBNP was mostly associated with baseline NT-proBNP. Changes in NT-proBNP were not 
directly correlated with age, BMI, eGFR and loop diuretics, but they are highly correlated 
with the baseline NT-proBNP, implying that a change in NT-proBNP was potentially related 
to age, BMI, eGFR and loop diuretics. The study showed that a change in NT-proBNP were 
not potentially associated with gender and ACE inhibitor. 
Several studies indicated that renal dysfunction influences NT-proBNP.8 9 24 10 25 Our results 
confirmed the previous studies that there was a negative association between eGFR and NT-
proBNP. One study26 showed that the absolute change in NT-proBNP at 5 years was 
associated with poorer renal function (eGFR) (standardized coefficient (r) = -0.12, p = 0.001), 
this was similar with our study that changes in NT-proBNP at 1 year was negatively 
associated with eGFR (r = -0.03, p = 0.06). Less information is available concerning the 
relationships between the changes in NT-proBNP and renal function. 
The SEM path analysis studies the possible direct and indirect factors of the variable 
simultaneously. This method has been applied for cardiovascular research field although with 
very limited applications.27 28 Our study showed that change in NT-proBNP at 1 year was not 
only considered with baseline NT-proBNP but also included the factors that were associated 
through baseline NT-proBNP, such as age, BMI, eGFR and taking loop diuretic to exploring 
their potential relationships fully (total effects). The correlations obtained from SEM method 
are more robust compared with separate multiple regressions due to use correlated error 
terms. In contrast, traditional multiple regression models assume that all predictors are 
independent; however, in reality these independent variables are always correlated to each 
other in some degrees, such as eGFR and age. As far as we know, this is a first article to 
apply SEM method in the field to investigate the relation between changes in NT-proBNP 
and renal function. Hope this study will give insight into understanding the relationship 
between NT-proBNP and renal function further in patients with suspected HF.   
Limitations  
This study was an observational study; the time point at 1 year was not exactly same for all 
patients. We also found that baseline sinus rhythm was negatively associated with baseline 
NT-proBNP (SR vs not SR, p<0.001) and changes in NT-proBNP (SR vs not SR, p<0.001) 
but their correlations were not very strong and were not included into the study. 
 
Conclusions 
In a model including age, sex, BMI, eGFR, loop diuretics, ACE inhibitor and NT-proBNP 
measured at baseline and follow-up, baseline NT-proBNP was the main determinant of 
subsequent change in NT-proBNP at 1 year.  
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Figure legend 
Figure 1: The path diagram showing the relationships amongst the variables: age, sex, BMI, 
eGFR, loop diuretics, ACE inhibitor, log10(NT-proBNP), changes in BMI, changes in eGFR 
and changes in log(NT-proBNP) from baseline to 12 months for the whole population. A line 
with one arrow represents a relationship between two variables, and the variable with the 
arrow pointing toward it is the dependent variable such as LogBNP_BL and LogDiff_BNP, 
and the other is the independent variable. The line with two arrows represents a possible 
correlation between the two variables. The e1, e2, e3 and e4 in circle represent error terms.  
Below are abbreviations for variables used in Figure 1:  
Age_BL: age at baseline 
BMI_BL: BMI at baseline  
eGFR_BL: eGFR at baseline  
ACE_BL: ACE inhibitor at baseline 
Loop_BL: loop diuretics at baseline 
LogBNP_BL: log(NT-proBNP) at baseline  
AbsoluteChangeBMI: an absolute change in BMI from baseline to 1-year  
AbsoluteChangeGFR: an absolute change in eGFR from baseline to 1-year 
LogDiff_BNP: an absolute change in NT-proBNP from baseline to 1-year, and then with a 
log-transformation. 
Figure 2: % changes of NT-proBNP  
Figure 3: Scatter plot between log(NT-proBNP) at 1 year and baseline (r=0.76, p<0.001) 
Figure 4: Scatter plot between eGFR at 1 year and baseline (r=0.81, p<0.001) 
Figure 5: The significant relationships (p<0.05) between changes in NT-proBNP 
(LogDiff_BNP) and variables: age, sex, BMI, eGFR, ACEi, loop diuretics, log(NT-proBNP), 
changes in BMI and changes in eGFR from baseline to 12 months apart from the 
relationships between changes in NT-proBNP with changes in eGFR (p=0.07) and baseline 
eGFR(p=0.06), and the relationship between taking loop diuretics and changes in eGFR 
(p=0.05) using structure equation modelling for the whole cohort of patients (n = 1006). The 
number (a standardized regression coefficient) shows how each independent variable 
influences the dependent variable. The higher the value the greater the impact of the 
independent variable on the dependent variable. The detailed information was shown in Table 
3. 
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Figure 1: The path diagram showing the relationships amongst the variables: age, sex, BMI, 
eGFR, loop diuretics, ACE inhibitor, log10(NT-proBNP), changes in BMI, changes in eGFR 
and changes in log(NT-proBNP) from baseline to 12 months for the whole population. A line 
with one arrow represents a relationship between two variables, and the variable with the 
arrow pointing toward it is the dependent variable such as LogBNP_BL and LogDiff_BNP, 
and the other is the independent variable. The line with two arrows represents a possible 
correlation between the two variables. The e1, e2, e3 and e4 in circle represent error terms.  
Below are abbreviations for variables used in Figure 1:  
Age_BL: age at baseline; 
BMI_BL: BMI at baseline;  
eGFR_BL: eGFR at baseline;  
ACE_BL: ACE inhibitor at baseline; 
Loop_BL: loop diuretics at baseline; 
LogBNP_BL: log(NT-proBNP) at baseline;  
AbsoluteChangeBMI: an absolute change in BMI from baseline to 1-year; 
AbsoluteChangeGFR: an absolute change in eGFR from baseline to 1-year; 
LogDiff_BNP: an absolute change in NT-proBNP from baseline to 1-year, and then with a 
log-transformation. 
 
 Figure 2: % changes of NT-proBNP  
 
 Figure 3: Scatter plot between log(NT-proBNP) at 1 year and baseline (r=0.76, p<0.001) 
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 Figure 4: Scatter plot between eGFR at 1 year and baseline (r=0.81, p<0.001) 
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 Figure 5: The significant relationships (p<0.05) between changes in NT-proBNP 
(LogDiff_BNP) and variables: age, sex, BMI, eGFR, ACEi, loop diuretics, log(NT-proBNP), 
changes in BMI and changes in eGFR from baseline to 12 months apart from the 
relationships between changes in NT-proBNP with changes in eGFR (p=0.07) and baseline 
eGFR(p=0.06), and the relationship between taking loop diuretics and changes in eGFR 
(p=0.05) using structure equation modelling for the whole cohort of patients (n = 1006). The 
number (a standardized regression coefficient) shows how each independent variable 
influences the dependent variable. The higher the value the greater the impact of the 
independent variable on the dependent variable. The detailed information was shown in Table 
3. 
 
Table 1: Baseline characteristics by three groups of the patients: whole population, patients 
with HF and patients in whom HF was refuted (not HF)  
 Missing 
values  
(N) 
Whole 
population 
(n =1006 ) 
HF 
(n = 882) 
Not HF 
(n =124 ) 
Age (years)  0 72 (63-78) 72 (64-78) 70 (61-75) 
Sex (male)  0 732 (73%) 651 (74%) 81 (65%) 
IHD (yes)  0 625 (62%) 554 (63%) 71 (57%) 
Diabetes  0 213 (21%) 187 (21%) 26 (21%) 
BMI  0 27.9 (24.9-31.4) 27.8 (24.8-31.2) 29.5 (25.8-34.0) 
COPD (yes)  0 106 (11%) 89 (10%) 17 (14%) 
Sinus rhythm (yes)  0 630 (63%) 529 (60%) 101 (82%) 
QRS width (msec)  96 108 (96-138) 111 (96-140) 97 (88-108) 
NYHA class (III/IV)  0 295 (29%) 276 (31%) 19 (15%) 
Systolic BP  53 132 (117-148) 131 (116-147) 139 (120-159) 
Heart rate  82 69 (60-82) 70 (60-83) 64 (57-76) 
LVI > Mild  0 668 (66%) 668 (76%) 0 
Left atrial dimension 
(cm)  
0 4.2 (3.8-4.8) 4.3 (3.9-4.8) 3.8 (3.5-4.3) 
NT-proBNP (pg/ml)  0 1106 (423-2605) 1340 (652-2935) 162 (88-272) 
NT-proBNP>400 pg/ml 0 769 (76%) 769 (87%) 0 
Sodium (mmol/L)  0 139 (137-141) 139 (137-141) 140 (138-142) 
Potassium (mmol/L)  3 4.4 (4.1-4.7) 4.4 (4.1-4.7) 4.4 (4.1-4.7) 
Urea (mmol/L)  0 6.7 (5.2-9.0) 6.8 (5.3-9.2) 5.9 (4.5-7.6) 
Creatinine (umol/L)  0 102 (86-125) 103 (87-128) 89 (80-105) 
eGFR (ml/min/1.73m2)  0 62 (49-75) 61 (48-74) 68 (60-83) 
Hb (g/dL)  46 13.6 (12.5-14.7) 13.6 (12.3-14.7) 13.8 (12.9-14.7) 
Loop diuretics (yes) 0 673 (67%) 621 (70%) 52 (42%) 
IHD, ischaemic heart disease; BMI, body mass index; COPD, chronic obstructive pulmonary 
disease; NYHA class, the New York Heart association; LVI, left ventricular impairment; 
eGFR, estimated glomerular filtration rate; Hb, haemoglobin. 
 
Table 2: Patients characteristics at baseline and follow up at one year with median and IQR  
 
 All patients Heart Failure 
 Baseline 1 year p-value* Baseline 1 year p-value* 
BMI 
27.9 
(25.0-31.4) 
28.0 
(25.0-31.8) 
 0.038  27.8 
(24.8-31.2) 
27.9 
(24.9-31.6) 
 0.042 
NT-proBNP 
(pg/ml)  
1106 
(423-2608) 
871 
(330-2003) 
<0.001 1340 
(652-2935) 
1040 
(448-2226) 
<0.001 
Urea (mmol/L)  
6.7 
(5.2-9.0) 
7.1 
(5.4-10.1) 
<0.001 6.8 
(5.3-9.2) 
7.3 
(5.5-10.5) 
<0.001 
Creatinine (umol/L)  
102 
(86-125) 
106 
(88-135) 
<0.001 103 
(87-128) 
108 
(90-137) 
<0.001 
eGFR 
(ml/min/1.73m2)  
61.9 
(49.4-75.1) 
58.7 
(44.3-73.9) 
<0.001 61.2 
(47.9-74.0) 
56.9 
(42.8-72.6) 
<0.001 
*Paired t-tests were used 
Table 3: The variables influencing NT-proBNP, changes in BMI, changes in eGFR and changes in NT-proBNP from baseline to 1 year using 
SEM method  
 Baseline NT-proBNP* Changes in NT-proBNP * Changes in BMI  Changes in eGFR  
 Estimate
d 
coefficie
nt 
S.E. Standardi
zed 
coefficie
nt 
p-value Estimat
ed 
coeffici
ent 
S.E. Standardi
zed 
coefficie
nt 
p-value Estimat
ed 
coeffici
ent 
S.E. Standardiz
ed 
coefficient 
p-value Estimate
d 
coefficie
nt 
S.E. Standardi
zed 
coefficie
nt 
p-
value 
Age 0.01 0.002 0.17 <0.01 -0.003 0.002 -0.02 0.14 -0.02 0.01 -0.14 0.003 -0.23 0.04 -0.19 <0.01 
Sex (male) -0.05 0.037 -0.04 0.176 - - - - - - - - -1.08 0.86 -0.04 0.21 
BMI -0.02 0.003 -0.17 <0.01 - - - - -0.12 0.01 -0.30 <0.01 - - - - 
eGFR -0.01 0.001 -0.21 <0.01 -0.002 0.001 -0.03 0.06 0.003 0.004 0.03 0.43 -0.27 0.02 -0.43 <0.01 
Loop 0.28 0.036 0.23 <0.01 -0.02 0.04 -0.01 0.65 0.39 0.16 0.07 0.01 -1.65 0.85 -0.07 0.05 
ACE 0.04 0.036 0.03 0.33 - - - - 0.17 0.15 0.03 0.27 -1.14 0.83 -0.04 0.17 
Log10(NT
-proBNP) 
- - - - 0.97 0.03 0.73 <0.001 -0.21 0.13 -0.06 0.11 -3.29 0.71 -0.15 <0.01 
Changes in 
BMI 
- - - - - - - - - - - - - - - - 
Changes in 
eGFR 
- - - - -0.002 0.001 -0.03 0.07 - - - - - - - - 
R2 0.23 0.56 0.09 0.14 
* log transformation with base 10. 
“ – “Assuming that there is no correlation between the two variables 
 
 
